Advance Nanotech Files Annual Report and Schedules Investor Conference Call; Advance Nanotech to Hold Investor Conference Call on Thursday, April 6, 2006
Selected highlights for 2005 include:
-- December 12, 2005 -- Advance Nanotech announced financing for epi-CNT in partnership with the University of Cambridge. The epi-CNT project (short for epitaxial growth of carbon nanotubes) will explore the development of a new inexpensive and precise method for the controlled growth of single wall carbon nanotubes.
-- November 4, 2005 -- Advance Nanotech subsidiary Owlstone Nanotech, Inc., a pioneer in the commercialization of nanotechnology-based chemical detection products, announced a testing and evaluation program with Kidde, the global fire and safety group and a subsidiary of United Technologies Corporation (NYSE:UTX). The Owlstone sensor, a nano-fabricated chemical detection system, is being tested for suitability in the next generation of its safety detection, prevention and protection systems.
-- October 13, 2005 -- Advance Nanotech investment Singular ID Pte. Ltd., a leading brand protection solution provider, announced that it signed an agreement with IMS Corporation Pte. Ltd., a subsidiary of the Singapore Exchange listed Advanced Integrated Manufacturing (AIM) Corp Group of Companies. Under this agreement, Singular ID and IMS Corporation will work together to design, develop and commercially manufacture scanners based on Singular ID's proprietary technology.
-- October 3, 2005 -- Advance Nanotech announced financing for BiMAT, a new technology that may aid in the early detection of Avian Influenza (Bird Flu) and other infectious diseases in humans and animals. One of the key applications for Advance Nanotech's BiMAT technology will be to enable first responder medics, EMTs and doctors to instantly analyze microscopic amounts biological material for specific diseases on site. BiMAT technology will eliminate the need to send samples to specialized laboratories, speeding treatment and reducing problems of handling, storage, mislabeling and treatment delay.
-- July 5, 2005 -- Advance Nanotech subsidiary Bio-Nano Sensium Technologies announced a limited beta test program of its wireless biosensor system. Under terms of the program, beta-stage versions of Bio-Nano Sensium (BNS) system will be available to potential partners and customers for evaluation.
-- March 3, 2005 -- Advance Nanotech announces that it has joined global businesses ALPS Electric Company Limited, Dow Corning Corporation and Marconi Corporation plc, to jointly fund a portfolio of strategic research and development work in electrical engineering at the University of Cambridge.
-- February 3, 2005 -- Advance Nanotech announced the final closing of a $20 million financing of common stock and the formation of, and initial appointments to, the company's Corporate Advisory Board. The company will use the proceeds from this round of financing for the further development of its portfolio.
During the course of 2005, Advance Nanotech completed the expansion of its senior management team recruiting Dr. Fred Allen, Dr. Michael Helmus and Dr. Peter Gammel to lead out its materials, biopharma and electronics business units respectively, Mr. Lowell Dashefsky as General Counsel and Dr. Claudio Marinelli as Entrepreneur in Residence at the University of Cambridge. Advance Nanotech promoted Mr. Thomas Finn MBA to Chief Financial Officer and recruited Mr. Drew Lewis to the position of Financial Controller. In 2005, Advance Nanotech also added Mr. Peter Rugg, Mr. Virgil Wenger CPA, Mr. Tony Goncalves CBM and Professor Bill Milne to its board of directors. Full biographical information may be found on the Advance Nanotech website: www.advancenanotech.com/management.html.
Advance Nanotech also announced today that it will conduct a conference call to update the investment community on its business activities on Thursday, April 6, 2006. Company executives will conduct the call at 10:30 a.m. Eastern Time. Interested participants should call (888) 538-0516 for domestic access or (706) 679-4832 for international access. Please reference Conference I.D. Number 7553858. There will be a playback available two hours after the conference call until midnight, May 6, 2006. To listen to the playback, please call (800) 642-1687 for domestic access or (706) 645-9291 for international access. Please reference Conference I.D. Number 7553858 for the replay.
About Advance Nanotech, Inc.
Advance Nanotech is dedicated to the successful commercialization of disruptive nanotechnologies to produce nano-enabled products. Advance provides financing and support services including commercialization guidance, project and infrastructure management, leadership assets, and counsel on intellectual property, licensing and regulatory issues to ensure maximum market potential. Advance Nanotech's diversified portfolio of 26 nanotechnologies, of which the company holds a majority stake in 21, impacts a range of applications including, but not limited to, sensors, medical therapeutics and composites. Advance is forging partnerships with leading manufacturers and universities in Europe, Asia and North America to transform innovative nanotechnology concepts into practical solutions. For more information on Advance Nanotech, please visit www.advancenanotech.com.
This document contains forward-looking statements by Advance Nanotech regarding its expectations as to its business, and involves risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those addressed in the forward-looking statements.
Factors that may cause such a difference include, but are not limited to, problems and risks associated with developments in the nanotechnology industry in general and in Advance Nanotech's products under development in particular; the potential failure of Advance Nanotech's products under development to prove safe and effective in application; uncertainties inherent in the early stage of Advance Nanotech's products under development; failure to successfully implement or complete research programmes; failure to receive marketing clearance from regulatory agencies for our products under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Advance Nanotech's business, structure or projections; the development of competing products; uncertainties related to Advance Nanotech's dependence on third parties and partners; and those risks described Advance Nanotech's filings with the SEC. Advance Nanotech disclaims any obligation to update these forward-looking statements.
Further information about these and other relevant risks and uncertainties may be found in the Advance Nanotech's findings with the Securities and Exchange Commission, all of which are available from the Commission as well as other sources.